Jamadagni Shrirang, Jamadagni Pallavi, Angom Binita, Mondal Dhirendranath, Upadhyay Sachchidanand, Gaidhani Sudesh, Hazra Jayram
Regional Ayurveda Institute for Fundamental Research, Nehru Garden, Gandhi Bhawan Road, Kothrud, Pune, 411038, India.
Regional Ayurveda Institute for Fundamental Research, Nehru Garden, Gandhi Bhawan Road, Kothrud, Pune, 411038, India.
J Ayurveda Integr Med. 2020 Oct-Dec;11(4):508-514. doi: 10.1016/j.jaim.2019.09.005. Epub 2020 Feb 5.
Aarogyavardhini Vati is a classical Ayurvedic herbomineral formulation. It contains mercury and copper compounds as principal minerals along with other minerals and herbal ingredients. Aarogyavardhini Vati is indicated in chronic liver ailments. However, safety concerns are often raised regarding the use of mercury containing ayurvedic drugs in disease conditions due to the risk of mercury and copper toxicity.
This study was performed to address the safety concerns regarding mercury and copper toxicity from Ayurvedic herbomineral formulations by investigating accumulation of these minerals in tissues and subsequent toxicity in chronic hepatotoxicity rat model.
Quantification of mercury and copper in Aarogyavardhini Vati was done. Chronic hepatotoxicity was induced in the Wistar rats by repeated administration of CCl for 8 weeks. Animals were treated with Aarogyavardhini Vati for various durations. Post treatment of 8 weeks, serum biochemical marker estimations was done. Estimation of mercury and copper from the liver, kidney and brain tissues was done after animal sacrifice. Histopathology evaluation of visceral organs was also performed.
Treatment with Aarogyavardhini Vati exhibited significant accumulation of mercury in the kidney but not in the brain and liver. Similarly, no significant accumulation of copper was observed in liver, kidney, and brain due to the treatment of Aarogyavardhini Vati. Serum biochemical and histopathological changes were not affected by the treatment with Aarogyavardhini Vati.
Aarogyavardhini Vati did not show any biologically significant potential to cause toxicity due to its mercury and copper content when administered for prolonged duration to rats with chronic hepatotoxicity.
阿罗吉亚瓦尔迪尼丸是一种经典的阿育吠陀草药矿物配方。它含有汞和铜化合物作为主要矿物质,以及其他矿物质和草药成分。阿罗吉亚瓦尔迪尼丸适用于慢性肝脏疾病。然而,由于存在汞和铜中毒的风险,在疾病状态下使用含汞的阿育吠陀药物时,人们常常会对其安全性表示担忧。
本研究旨在通过调查这些矿物质在慢性肝毒性大鼠模型组织中的蓄积情况以及随后的毒性,来解决阿育吠陀草药矿物配方中汞和铜毒性的安全性问题。
对阿罗吉亚瓦尔迪尼丸中的汞和铜进行定量分析。通过反复给予四氯化碳8周,在Wistar大鼠中诱导慢性肝毒性。用阿罗吉亚瓦尔迪尼丸对动物进行不同时长的治疗。治疗8周后,进行血清生化标志物评估。在动物处死后,对肝脏、肾脏和脑组织中的汞和铜进行测定。还对内脏器官进行了组织病理学评估。
用阿罗吉亚瓦尔迪尼丸治疗后,肾脏中汞有显著蓄积,但在脑和肝脏中没有。同样,用阿罗吉亚瓦尔迪尼丸治疗后,在肝脏、肾脏和脑中未观察到铜的显著蓄积。血清生化和组织病理学变化不受阿罗吉亚瓦尔迪尼丸治疗的影响。
当对慢性肝毒性大鼠长期给药时,阿罗吉亚瓦尔迪尼丸因其汞和铜含量并未显示出任何具有生物学意义的潜在毒性。